Lightnews — Scholar-powered news

MiLaboratories @milaboratories.bsky.social · 19h

Congratulations to Nobel Laureate Shimon Sakaguchi for his groundbreaking work on regulatory T cells! 🧬

We're proud to see our technology, MiXCR, supporting his lab’s research. In a recent study, MiXCR helped the team decode TCR repertoires.

Proud to support science that changes the world. 🌍

1

MiLaboratories @milaboratories.bsky.social · 1d

Biologists design brilliant experiments...then lose momentum waiting for results.

That’s why we built Platforma, to put the power of analysis directly into biologists’ hands.

🎥 Watch the demo to see how Platforma takes you from raw data to validated T-cell insights, without any coding.

MiLaboratories @milaboratories.bsky.social · 6d

October is Breast Cancer Awareness Month, a timely moment to spotlight new advances in how we understand and treat this disease. 🎗️

A recently study explores dynamic systemic immune responses in early-stage HR+ patients receiving chemotherapy + immunotherapy.

Read more here: shorturl.at/jOQkO

1

MiLaboratories @milaboratories.bsky.social · 8d

Fast insights from single-cell data without coding

With Platforma, you can:
🔹 Explore UMAPs & Leiden clusters
🔹 Integrate transcriptomics + VDJ metrics
🔹 Visualize clonotypes & sequence similarities
🔹 Overlay gene expression across clusters

🎥 youtu.be/FrsS3YDauhg

#singlecell #VDJ #NGS

Single-Cell Multi-Omics Analysis | UMAP, Clustering & Gene Expression in Platforma

YouTube video by MiLaboratories

youtu.be

1 4

MiLaboratories @milaboratories.bsky.social · 13d

A new study from @ox.ac.uk shows why HR+ patients with lymph node metastasis fare worse:
- Weakened Defense: Tumor-reactive CD8 T cells are scarce, impairing cancer surveillance.
- Early-Stage Window: Early HR+ patients have a robust, diverse circulating CD8 TCR

More details: shorturl.at/0HP2l

2

MiLaboratories @milaboratories.bsky.social · 14d

We’re thrilled to team up with @yefis-immunology.bsky.social for our next webinar!

📅 October 7th, 16:00 CET

Platforma was built to make cutting-edge bioinformatics accessible to every scientist, so anyone can turn raw NGS into meaningful insights without coding.

🔗 Register here: shorturl.at/AQtCD

1

MiLaboratories @milaboratories.bsky.social · 15d

Last week we hosted a webinar with Kiel University and shared valuable insights on T-cell responses against EBV (Epstein–Barr Virus) and its implications for advancing research and therapeutic development.

Weren't able to attend?

🎥 Watch the recording here: www.youtube.com/watch?v=l2Q8...

2

MiLaboratories @milaboratories.bsky.social · 15d

💡Why repertoire clonality matters and how to analyze it

Done right, repertoire analysis transforms sequencing data into actionable insights for immune monitoring and therapy evaluation.

bit.ly/4gBZlRp

How to Analyze TCR/BCR Repertoire Diversity and Clonality

Learn what immune repertoire diversity is, key clonality metrics, why downsampling matters, and how to visualize TCR/BCR repertoires for immune profiling.

open.substack.com

1

MiLaboratories @milaboratories.bsky.social · 20d

Location, location, location.

Developing a multimodal framework, new research from @bcmhouston.bsky.social reveals that a T cell's location within a tumor is a major factor influencing its function.

We're proud that MiXCR enabled comprehensive TCR repertoire profiling in this study.

MiLaboratories @milaboratories.bsky.social · 21d

Prioritizing antibody candidates shouldn’t require coding bioinformatics expertise. With Platforma, biologists in academia or pharma can analyze NGS data independently, explore motifs, predict liabilities, and select the best antibody leads with confidence.

#antibody #bcr #bioinformatics

MiLaboratories @milaboratories.bsky.social · 22d

🚨 Last chance to register!

We’re going live tomorrow to explore the link between Epstein-Barr Virus (EBV) and Primary Sclerosing Cholangitis (PSC) with insights from large-scale immune profiling.

📅 Wednesday, Sep 17 @ 3:00 PM GMT+2
💻 Live demo included

Register here: shorturl.at/E4tpj

Interactive Session with the Research Team: T and B Cell Responses Against Epstein-Barr Virus in PSC · Zoom · Luma

Join us for an exclusive interactive session with the authors of the groundbreaking Nature Medicine article, "T and B cell responses against Epstein-Barr virus…

shorturl.at

1

MiLaboratories @milaboratories.bsky.social · 29d

🌍 Exciting news! We’ve launched the Platforma Ambassador Program—a chance for researchers to host workshops, lead user groups, and join a global network of innovators in bioinformatics. Gain training, travel grants & career growth.

Apply by Sept 21 👉 shorturl.at/KN2Ju

Launching the Platforma Ambassador Program

Empowering the next generation of scientists to connect, collaborate, and accelerate discovery

shorturl.at

3

MiLaboratories @milaboratories.bsky.social · Sep 4

For the first time, CLL's immune dysfunction has been mapped at single-cell resolution. A new @nature.com study reveals galectin-9 is a key driver of T-cell exhaustion and linked to worse outcomes.

Using MiXCR, scientists reconstructed TCR repertoires to uncover these dynamics

#CLL #TCell #TCR

2

MiLaboratories @milaboratories.bsky.social · Aug 28

Now, hear directly from the scientists behind the study! 🎙️

Join lead author Hesham + team for an interactive webinar:

- Deep dive into methods
- Live demo of TCR analysis
- Future directions

🔗 Register here: shorturl.at/6NHZb

Interactive Session with the Research Team: T and B Cell Responses Against Epstein-Barr Virus in PSC · Zoom · Luma

Join us for an exclusive interactive session with the authors of the groundbreaking Nature Medicine article, "T and B cell responses against Epstein-Barr virus…

shorturl.at

MiLaboratories @milaboratories.bsky.social · Aug 28

📊 Researchers found:

- PSC patients show elevated T & B cell responses against EBV (1,008 PSC-associated TCR clonotypes).
- EBV-targeting antibodies confirmed in PSC liver tissue.
- Health data (116M+ records) links mono to PSC (odds ratio 12).

1 1

MiLaboratories @milaboratories.bsky.social · Aug 28

🦠 Could Epstein–Barr virus (EBV) be a hidden driver of chronic liver disease?

A new Nature Medicine study shows EBV may play a major role in primary sclerosing cholangitis (PSC).

🧵 Key findings ⬇️

1 2

MiLaboratories @milaboratories.bsky.social · Aug 22

9 patients. 40 months. 0 recurrences. 💉

A new Nature study shows the power of personalized cancer vaccines. With the help of MiXCR, researchers designed vaccines targeting each patient’s tumor profile, leading to strong T cell responses.

A big step for immunotherapy in hard-to-treat cancers.

1

MiLaboratories @milaboratories.bsky.social · Aug 19

✨ Feeling the energy at IUIS! The excitement is contagious, and we loved sharing a live demo of Platforma with so many of you today.

🚀 If you missed it, no worries — we’ll be back tomorrow at 11 AM at the Cellecta booth. Come by to see the future of immune profiling.

MiLaboratories @milaboratories.bsky.social · Aug 13

How long does vaccine protection actually last?

A @nature.com study on Ebola vaccines found B cell immunity still going strong 4+ years later.

MiXCR enabled early gene expression predicted antibody levels and uncovered targeted clonal expansion

Try MiXCR on Platforma for free (link in bio)

1

MiLaboratories @milaboratories.bsky.social · Aug 12

💡 Unlock immune insights in minutes, no coding required!

Join us at @iuis-online.bsky.social in Vienna for a live demo of Platforma that will change the way you work with NGS data.

📅 Aug 19 @ 15:00–15:30
📅 Aug 20 @ 11:00–11:30
📍 Booth #75

Limited spots, so don't wait to sign up: tally.so/r/w4b8er

2

MiLaboratories @milaboratories.bsky.social · Aug 7

A new study in @nature.com reveals how TCRs recognize neoantigens.

They found that a specific mutation creates a stable binding site that helps T cells identify tumor cells.

We're proud that MiXCR enabled the structural characterization of tumor-reactive TCRs.

Read more here: shorturl.at/Pppzn

MiLaboratories @milaboratories.bsky.social · Aug 6

We're excited to attend the @iuis-online.bsky.social conference in Vienna!

Whether you're working on TCR/BCR discovery, single-cell data, or vaccine development, Platforma can take you from raw NGS data to high-potential candidates, no coding required.

📅 Meet with us: shorturl.at/ufaTF

calendar.app.google

MiLaboratories @milaboratories.bsky.social · Aug 5

Great news - MiXCR just got even easier to use.

You're using the exact same trusted MiXCR engine, now boosted with Platforma's GUI and powerful downstream analysis tools. And - it’s still completely free for academia.

📽️ Watch this short video and accelerate your research today: shorturl.at/dZdEp

1

MiLaboratories @milaboratories.bsky.social · Aug 5

We're hiring!

Are you passionate about science and communication? Do you love helping others understand complex topics and solving problems? Join our team in Bilbao as a Documentation Writer and Bioinformatics Support Agent!

lnkd.in/eqxu3bts

MiLaboratories hiring Documentation writer and bioinformatics support agent in Bilbao, Basque Country, Spain | LinkedIn

Posted 10:28:50 PM. Company DescriptionMiLaboratories is transforming the way biologists turn data into discoveries…See this and similar jobs on LinkedIn.

lnkd.in

2

MiLaboratories @milaboratories.bsky.social · Jul 31

🫀 New in Nature Cardiovascular Research: APOB-reactive CD4⁺ T cells shift from regulatory to pro-inflammatory in severe CAD.

🔬 Using AIM assays + transcriptomics, researchers uncovered key immune drivers of atherosclerosis—powered by MiXCR for TCR tracking.

Full article: shorturl.at/N3dDk

Loss of effector Treg signature in APOB-reactive CD4+ T cells in patients with coronary artery disease - Nature Cardiovascular Research

By characterizing APOB-reactive CD4+ T cells in patients with atherosclerosis, Roy et al. identify effector regulatory T (eTreg) cells as the predominant autoreactive subset. These APOB-specific eTreg...

shorturl.at

1